Mucoadhesive Micelle Nanoparticles: A New Dosing Paradigm for Glaucoma Treatment

Effective glaucoma management is hindered by poor patient adherence to daily eye drop regimens. We have developed a sustained-release ocular formulation using mucoadhesive micelle nanoparticles (MNPs) that deliver latanoprost directly at the ocular surface with fewer doses. Unlike traditional formulations, the MNPs are engineered to remain on the eye’s mucosal layer without penetrating underlying tissues, providing a controlled and extended release of drug precisely where it is needed. Here we demonstrate the tolerability and efficacy of these drops using latanoprost.